Cvrx, INC

CVRx, Inc. announced the departure of its Chief Revenue Officer, Robert John, and the appointment of Paul Verrastro as Interim Head of Sales.

CVRx, Inc. reports the resignation of CFO Jared Oasheim, detailing his transition plan, consulting role, and compensation package.

CVRx, Inc. reported voting results from its 2026 annual meeting of stockholders, including the election of directors and ratification of its independent auditor.

CVRx, Inc. announced first quarter 2026 financial and operating results, highlighting a 20% increase in total revenue to $14.8 million and a 22% rise in U.S. revenue to $13.7 million, driven by expanded sales territories and increased physician awareness of its Barostim therapy.

CVRx, Inc. announced preliminary Q1 2026 financial results showing approximately 20% revenue growth, improved gross margins, and positive early data on prior authorization approval rates.

CVRx, Inc. approved performance stock units for executive officers tied to a confidential cumulative revenue goal for fiscal years 2026-2027.

CVRx, Inc. announced its first quarter 2026 financial results, showcasing a 20% increase in revenue driven by strong U.S. sales, while also reporting a slight reduction in net loss compared to the prior year period.

CVRx, Inc. reported a 10% revenue increase in Q3 2025, driven by U.S. Barostim sales and improved gross margins, despite continued net losses.

CVRx, Inc. announced a 15% revenue increase for Q2 2025, driven by U.S. Barostim sales, while continuing to incur net losses as it invests in commercialization.

CVRx, Inc. reports a 15% increase in revenue for the first quarter of 2025, primarily driven by growth in U.S. sales of its Barostim device for heart failure.

CVRx, Inc. announced a 27% increase in revenue for the third quarter of 2024, primarily driven by growth in U.S. sales of its Barostim device.

CVRx, Inc. announced a 29% increase in revenue for the second quarter of 2024, primarily driven by strong growth in U.S. sales of its Barostim device.

CVRx, Inc. reported a 10% increase in revenue to $56.7 million for fiscal year 2025, driven by U.S. sales growth and expanded market opportunities for its Barostim therapy.

CVRx's 2024 10-K filing reveals a revenue increase to $51.3 million and an expanded market opportunity for its Barostim therapy.

CVRx, Inc. reported a revenue increase to $39.3 million and a net loss of $41.2 million for the year ended December 31, 2023, highlighting growth in U.S. sales of its Barostim device.

Brent Binkowski, CHIEF OPERATING OFFICER of CVRx, Inc., purchased 26,223 shares of common stock on August 13, 2026 for $2.91 per share.

Brent Binkowski, CHIEF OPERATING OFFICER of CVRx, Inc., sold 1,309 shares of common stock on August 12, 2026 for $2.55 per share.

Director Kirk G. Nielsen acquired 8,720 shares of common stock and 11,182 stock options as part of an annual equity grant.

Director Mudit K. Jain acquired 8,720 shares of common stock and 11,182 stock options as part of an annual equity grant.

Director Joseph P. Slattery acquired 8,720 shares of common stock and 11,182 stock options in CVRx, Inc.

Director Mitch C. Hill acquired 8,720 shares of common stock and 11,182 stock options as part of an annual equity grant.

CVRx, Inc. has issued its proxy statement for the 2026 annual meeting of stockholders to be held virtually on June 1, 2026.

CVRx, Inc. has filed a definitive proxy statement with the SEC.

CVRx, Inc. will hold its 2025 annual meeting of stockholders virtually on June 3, 2025, to elect two Class I directors and ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm.

CVRx, Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

CVRx, Inc. announces its annual stockholders meeting to be held virtually on June 4, 2024, featuring proposals including the election of directors, ratification of the accounting firm, and an amendment to allow officer exculpation.

New Enterprise Associates (NEA) has filed an Amendment No. 2 to its Schedule 13D, reporting a decrease in its beneficial ownership of CVRx, Inc. common stock to 7.8% due to an increase in the total shares outstanding.

Gilde Healthcare entities have filed an Amendment No. 3 to their Schedule 13D, disclosing that their beneficial ownership in CVRx, Inc. has fallen below the 5% reporting threshold as of February 4, 2025.

Jorey Chernett has reported beneficial ownership of 1,461,750 shares, representing 5.5% of CVRx, Inc.'s outstanding common stock as of August 7, 2026.

Johnson & Johnson and its subsidiary, JJDC, Inc., have reported a continued beneficial ownership of 15.4% in CVRx, Inc. common stock.

Vensana Capital and its managing directors have filed an Amendment No. 3 to their Schedule 13G, confirming their beneficial ownership of over 7% of CVRx, Inc.'s common stock as of December 31, 2024.